Prevalence and predictors of fragility fractures in systemic lupus erythematosus

Annals of the Rheumatic Diseases

Volumn 64, Issue 1, 2005, Pages 111-113

  Yee, C S ^a   Crabtree, N ^b   Skan, J ^a   Amft, N ^a   Bowman, S ^b   Situnayake, D ^c   Gordon, Caroline ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

^c CITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PREDNISOLONE;

ADULT; AFRICAN CARIBBEAN; AGE; AGED; ARTICLE; BODY MASS; BONE DENSITY; BONE MINERAL; BONE MINERAL DENSITOMETRY; DISEASE ASSOCIATION; FEMALE; FRACTURE; FRAGILITY FRACTURE; HUMAN; MAJOR CLINICAL STUDY; MALE; MENOPAUSE; OSTEOPOROSIS; PREVALENCE; PRIORITY JOURNAL; RACE DIFFERENCE; RISK FACTOR; SCORING SYSTEM; STATISTICAL SIGNIFICANCE; STEROID THERAPY; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC LUPUS INTERNATIONAL COLLABORATING CLINICS AMERICAL COLLEGE OF RHEUMATOLOGY DAMAGE INDEX;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; BONE DENSITY; CROSS-SECTIONAL STUDIES; ENGLAND; FEMALE; FRACTURES, BONE; GLUCOCORTICOIDS; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; OSTEOPOROSIS; PREDNISOLONE; PREVALENCE; RISK FACTORS;

EID: 11344263144     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2003.018127     Document Type: Article

References (19)

1. Dhillon VB, Davies MC, Hall ML, Round JM, Ell PJ, Jacobs HS, et al. Assessment of the effect of oral corticosteroids on bone mineral density in systemic lupus erythematosus: a preliminary study with dual energy x ray absorptiometry. Ann Rheum Dis 1990;49:624-6.
2. Formiga F, Moga I, Nolla JM, Pac M, Mitjavila F, Roig-Escofet D. Loss of bone mineral density in premenopausal women with systemic lupus erythematosus. Ann Rheum Dis 1995;54:274-6.
3. Kalla AA, Kotze TJ, Meyers OL. Metacarpal bone mass in systemic lupus erythematosus. Clin Rheumatol 1992;11:1-8.
4. Kalla AA, Fataar AB, Jessop SJ, Bewerunge L. Loss of trabecular bone mineral density in systemic lupus erythematosus. Arthritis Rheum 1993;36:1726-34.
5. Kipen Y, Buchbinder R, Forbes A, Strauss B, Littlejohn G, Morand E. Prevalence of reduced bone mineral density in systemic lupus erythematosus and the role of steroids. J Rheumatol 1997;24:1922-9.
6. Sels F, Dequeker J, Verwilghen J, Mbuyi-Muamba J-M. SLE and osteoparosis: dependence and/or independence on glucocorticoids. Lupus 1996;5:89-92.
7. Rons F, Peris P, Guanabens N, Font J, Huguet M, Espinosa G, et al. The effect of systemic lupus erythematosus and long-term steroid therapy on bone mass in pre-menopausal women. Br J Rheumatol I995;34:742-7.
8. Ramsey-Goldman R, Dunn JE, Huang C-F, Dunlop D, Rairie JE, Fitzgerald S, et al. Frequency of fractures in women with systemic lupus erythematosus. Arthritis Rheum 1999;42:882-90.
9. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7.
10. Isenberg DA, Gordon C, British Isles Lupus Assessment Group. From BILAG to BLIPS - disease activity assessment in lupus past, present and future, Lupus 2000;9:651-4.
11. Gladman D, Goldsmith C, Urowitz M, Bacon P, Fortin P, Ginzler E, et al. The Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) damage index for systemic lupus erythematosus international comparison. J Rheumatol 2000;27:373-6.
12. World Health Organisation. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Technical Report Series 843. Geneva: WHO, 1994.
13. Zonana-Nacach A, Barr SG, Magder LS, Petri M. Damage in systemic lupus erythematosus and its association with corticosteroids. Arthritis Rheum 2000;43:1801-8.
14. Melton U, Marquez MA, Achenbach SJ, Tefferi A, O'Connor MK, O'Fallon WM, et al. Variation in bone density among persons of African heritage. Osteoporosis Inf 2002;13:551-9.
15. Guideline Writing Group for Bone and Tooth Society, National Osteoporosis Society and Royal College of Physicians. Glucocorticoid-induced osteoporosis: guidelines for prevention and treatment. London: Royal College of Physicians, 2002.
16. van Stoa TP, Laan RF, Barton IP, Cohen S, Reid DM, Cooper C. Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy. Arthritis Rheum 2003;48:3224-9.
17. Adachi JD, Bensen WG, Brown J, Hanley D, Hodsman A, Josse R, et al. Intermittent etidronate therapy to prevent corticosteroid-induced osteoparosis. N Engl J Med 1997;337:382-7.
18. Saag KG, Emkey R, Schnitzer TJ, Brown JP, Hawlcins F, Goemaere S, et al. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. N Engl J Med 1998;339:292-9.
19. Cohen S, Levy RM, Keller M, Baling E, Emkey RD, Greenwald M, et al. Risedronate therapy prevents corticosteroid-induced bone loss. A twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum 1999;42:2309-18.